Skip to main content
news
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang

 

Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.

The total transaction amount is approximately $2 billion, marking the largest take-private deal announced so far this year.

Haiwen & Partners served as legal counsel to one of the consortium members of the offeror, China State-Owned Enterprise Mixed Ownership Reform Fund, providing legal services in both Mainland China and Hong Kong. Meanwhile, Clifford Chance acted as the legal advisor to CITIC Securities, the financial advisor to the offeror.

The consortium behind the offeror comprises the Mixed Ownership Fund, Sinopharm (Hong Kong), Advanced Manufacturing Industry Investment Fund Phase II, China Reform Development Investment Management, Chongqing Fuling Industry Development Group, and Red Investment Limited.

China TCM primarily engages in the production and sale of traditional Chinese medicine and pharmaceutical products, focusing on Chinese medicine granules, patent medicines, and Chinese medicinal slices. China TCM has been listed in Hong Kong since 1993.

The Haiwen team was led by partners Wu Zuolong and Lin Xixiang, while partner Tommy Tam led the Clifford Chance team.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

NO&T, STB, AMT, Davis Polk advise on Japan's biggest IPO in 6 years

by Asian Legal Business《亚洲法律杂志》 |

Nagashima Ohno & Tsunematsu and Simpson Thacher & Bartlett have advised Tokyo Metro on its 348.6 billion yen ($2.3 billion) initial public offering, Japan's largest in six years.

Deals

CAM, Trilegal act on Adani’s latest $500mln QIP

by Nimitt Dixit |

Cyril Amarchand Mangaldas has represented Adani Enterprises, the Adani Group’s flagship entity, on its $500 million qualified institutional placement, with Trilegal advising the placement agents SBI Capital Markets, Jefferies India, and ICICI Securities.

Deals

CAM, Khaitan guide latest major India cement M&A

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising the Adani-held Ambuja Cement on its acquisition of 46.8 percent controlling stake in Orient Cement (OCL) for approximately $451 million. Khaitan & Co is representing OCL on the deal.